EntryPoint Capital LLC Makes New $420,000 Investment in 10x Genomics $TXG

EntryPoint Capital LLC purchased a new position in 10x Genomics (NASDAQ:TXG) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 48,137 shares of the company’s stock, valued at approximately $420,000.

Several other hedge funds have also added to or reduced their stakes in the business. LPL Financial LLC increased its position in shares of 10x Genomics by 26.2% in the fourth quarter. LPL Financial LLC now owns 33,771 shares of the company’s stock valued at $485,000 after acquiring an additional 7,014 shares during the period. Russell Investments Group Ltd. increased its position in shares of 10x Genomics by 70.1% in the fourth quarter. Russell Investments Group Ltd. now owns 16,818 shares of the company’s stock valued at $242,000 after acquiring an additional 6,932 shares during the period. Invesco Ltd. increased its position in shares of 10x Genomics by 21.8% in the fourth quarter. Invesco Ltd. now owns 118,067 shares of the company’s stock valued at $1,695,000 after acquiring an additional 21,134 shares during the period. Raymond James Financial Inc. purchased a new position in shares of 10x Genomics in the fourth quarter valued at about $431,000. Finally, Canada Pension Plan Investment Board increased its position in shares of 10x Genomics by 27.1% in the fourth quarter. Canada Pension Plan Investment Board now owns 200,200 shares of the company’s stock valued at $2,875,000 after acquiring an additional 42,700 shares during the period. 84.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on TXG. Stephens restated an “overweight” rating and issued a $14.00 price objective on shares of 10x Genomics in a research report on Thursday, May 15th. The Goldman Sachs Group decreased their price objective on shares of 10x Genomics from $7.50 to $6.50 and set a “sell” rating on the stock in a research report on Monday, May 12th. Barclays restated an “overweight” rating and issued a $15.00 price objective (up previously from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. UBS Group boosted their price target on shares of 10x Genomics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Finally, Bank of America boosted their price target on shares of 10x Genomics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Thursday, June 26th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $13.54.

10x Genomics Stock Performance

Shares of TXG opened at $13.36 on Thursday. The stock has a market cap of $1.66 billion, a PE ratio of -19.09 and a beta of 2.03. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $24.76. The firm’s 50-day simple moving average is $12.46 and its two-hundred day simple moving average is $10.69.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.63. The business had revenue of $172.91 million for the quarter, compared to analysts’ expectations of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The business’s revenue was up 12.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. Equities research analysts predict that 10x Genomics will post -1.43 EPS for the current year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.